New Blood-Clotting Injection for Hemophilia and Factor VII Deficiency
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This early-stage trial tests a new injectable medicine called SR604 designed to help people with hemophilia A, hemophilia B, or congenital Factor VII deficiency—conditions where the blood doesn't clot properly. The study will look at how safe the medicine is and whether it reduces bleeding episodes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have hemophilia A, hemophilia B, or congenital Factor VII deficiency confirmed by blood tests
- You have had recent bleeding episodes that needed treatment (at least 3 in the past 3 months for hemophilia, or 2 for Factor VII deficiency)
- You have accessible medical records of your bleeding and treatment for at least 3 months before enrollment
- You do not have hepatitis B, HIV, syphilis, or active hepatitis C
- You are not currently taking blood thinners, anti-inflammatory drugs (like aspirin), or certain other medicines that affect bleeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called SR604 to see if it is safe and how it works in the body. It is for healthy men and for people with hemophilia A, hemophilia B, or factor VII deficiency who have frequent bleeding or are on preventive treatment.
This trial is testing a new injection called SR604 in people with congenital factor VII deficiency, a rare bleeding disorder. The study will check if the drug is safe and effective at preventing or treating bleeding episodes.
This trial tests a new injection called GS1191-0445 for people with hemophilia A. It aims to see if it is safe and works well to prevent or treat bleeding episodes.
This trial tests a new gene therapy called SPK-8011QQ for adults with severe or moderately severe hemophilia A. The goal is to see if a single infusion can help your body produce its own factor VIII, reducing or stopping the need for regular factor VIII injections.
This trial tests a gene therapy to help your body produce more of the clotting protein (factor VIII) it's missing. It may reduce or stop the need for regular factor infusions.
This trial tests a single dose of ANB-002, an experimental therapy for hemophilia B. It aims to see if the drug is safe and effective for people with severe hemophilia B who have been treated with factor IX before and do not have inhibitors.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.